Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Peptide Comparison

OrforglipronvsTirzepatide

First oral non-peptide GLP-1 receptor agonist for diabetes and obesity

The dual-action powerhouse that targets both GIP and GLP-1 receptors, delivering the most dramatic weight loss results ever seen in a medication—averaging over 20% body weight reduction while also crushing blood sugar levels in people with diabetes.

Weight ManagementWeight Management

At a Glance

Quick
comparison

Dose Range

Orforglipron

12 mg–36 mg mg

Tirzepatide

2.5–15 mg

Frequency

Orforglipron

Once daily

Tirzepatide

Once weekly

Administration

Orforglipron

oral

Tirzepatide

Subcutaneous injection

Cycle Length

Orforglipron

Ongoing/indefinite

Tirzepatide

Ongoing/indefinite

Onset Speed

Orforglipron

Moderate (1-2 weeks)

Tirzepatide

Moderate (1-2 weeks)

Evidence Level

Orforglipron

Strong human trials (Phase 3 or FDA approved)

Tirzepatide

Strong human trials (Phase 3 or FDA approved)

Efficacy

Benefit
ratings

Orforglipron
Tirzepatide

Weight Management

Orforglipron9%
Tirzepatide0%

Blood Sugar Control

Orforglipron9%
Tirzepatide96%

Cardiovascular Health

Orforglipron7%
Tirzepatide0%

Weight Loss

Orforglipron0%
Tirzepatide99%

Appetite Control

Orforglipron0%
Tirzepatide97%

Technical Data

Compound
specifications

Orforglipron

Molecular Formula

C48H48F2N10O5

Molecular Weight

883.0 Da

Half-Life

25-68 hours (dose-dependent; enables once-daily oral dosing)

Bioavailability

~79% oral bioavailability (food-independent)

CAS Number

2212020-52-3

Tirzepatide

Molecular Formula

C225H348N48O68

Molecular Weight

4813.45 g/mol

Half-Life

Approximately 5 days (120 hours)

Bioavailability

~80% (subcutaneous)

CAS Number

2023788-19-2

Protocols

Dosing
tiers

Orforglipron

Tirzepatide

starting

2.5 mg

Once weekly

4 weeks

This introductory dose helps your body adjust to the medication and minimizes GI side effects. Don't expect much weight loss yet—this phase is all about building tolerance. Think of it as your body's training wheels period.

standard

5-10 mg

Once weekly

4+ weeks at each dose

After 4 weeks at 2.5mg, increase to 5mg. Stay here for at least 4 weeks, then move to 7.5mg, then 10mg. This gradual climb reduces side effects while ramping up the weight loss. Most people start seeing serious results at 5-10mg doses.

advanced

12.5-15 mg

Once weekly

Ongoing/maintenance

The 15mg dose delivers maximum weight loss—averaging over 20% of body weight in trials. Continue increasing by 2.5mg every 4 weeks until reaching 15mg or your optimal maintenance dose. This is where the jaw-dropping results happen.

Applications

Best
suited for

Orforglipron

Oral GLP-1 receptor agonism without injection burden

Orforglipron is particularly well-suited for individuals focused on oral glp-1 receptor agonism without injection burden. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Weight management in obesity with or without type 2 diabetes

Orforglipron is particularly well-suited for individuals focused on weight management in obesity with or without type 2 diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Glycemic control in type 2 diabetes as add-on to metformin

Orforglipron is particularly well-suited for individuals focused on glycemic control in type 2 diabetes as add-on to metformin. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Cardiovascular risk reduction through weight loss and metabolic improvements

Orforglipron is particularly well-suited for individuals focused on cardiovascular risk reduction through weight loss and metabolic improvements. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Tirzepatide

People Who Want Maximum Weight Loss Results

If you're serious about losing significant weight, tirzepatide delivers results that were previously only achievable through bariatric surgery. Clinical trials showed average weight loss exceeding 20% of body weight—that's 50+ pounds for someone starting at 250 pounds. No other medication comes close.

Those Who Haven't Succeeded with Semaglutide

Thanks to its dual GIP/GLP-1 mechanism, tirzepatide often works better for people who had limited results with GLP-1-only drugs like semaglutide. The added GIP activation provides extra metabolic benefits that can break through plateaus and deliver superior weight loss.

People with Type 2 Diabetes Needing Aggressive Control

Head-to-head trials proved tirzepatide beats semaglutide for blood sugar control. The average HbA1c reduction of over 2 percentage points means many people can dramatically reduce or eliminate other diabetes medications. It's a genuine game-changer for metabolic health.

Individuals Looking to Transform Their Relationship with Food

Tirzepatide doesn't just reduce hunger—it fundamentally changes how food appeals to you. Users describe feeling free from constant food thoughts, finding it easy to stop eating when satisfied, and losing interest in formerly irresistible treats. It's not willpower—it's biochemistry working for you.

Safety Profile

Side
effects

Orforglipron

Common

  • Nausea
  • Constipation
  • Diarrhea
  • Vomiting

Uncommon

  • Heart Rate Increase

Serious

  • Pancreatitis Risk

Tirzepatide

Common

  • Nausea
  • Diarrhea
  • Decreased Appetite
  • Vomiting

Uncommon

  • Gallbladder Problems
  • Hair Thinning (Telogen Effluvium)

Serious

  • Pancreatitis
  • Thyroid Tumors (Theoretical Risk)

Research Status

Safety
& evidence

Orforglipron

Evidence Level

Strong human trials (Phase 3 or FDA approved)

FDA Status

Research compound

Safety Overview

Orforglipron (MK-0731) completed Phase II trials for type 2 diabetes with favorable safety profile at oral doses of 10-40 mg daily. Gastrointestinal side effects (nausea, vomiting) occurred in 20-30% of subjects but were dose-dependent and generally mild. As a GLP-1 receptor agonist, risks include potential medullary thyroid carcinoma (black box warning category) and acute pancreatitis, requiring thyroid screening before treatment initiation and patient education on symptoms.

Contraindications

  • xPersonal or family history of medullary thyroid carcinoma (GLP-1 class precaution)
  • xMultiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • xKnown hypersensitivity to orforglipron or excipients
  • xHistory of pancreatitis (use with caution)

Tirzepatide

Evidence Level

Strong human trials (Phase 3 or FDA approved)

FDA Status

FDA approved for this use

Safety Overview

Tirzepatide has been extensively studied in the SURPASS (diabetes) and SURMOUNT (obesity) trial programs, involving thousands of participants over multiple years. The FDA approved it after thorough safety review. While GI side effects are common (especially during dose increases), they're typically mild to moderate and improve over time. Serious adverse events are rare. The SURPASS-CVOT trial is ongoing to evaluate long-term cardiovascular outcomes.

Contraindications

  • xPersonal or family history of medullary thyroid carcinoma (MTC)
  • xMultiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • xHistory of serious allergic reaction to tirzepatide or any GLP-1/GIP medication
  • xCurrent or recent pancreatitis
  • xPregnancy or planning to become pregnant

Decision Guide

Which is
right for you?

Choose Orforglipron if...

  • Oral GLP-1 receptor agonism without injection burden
  • Weight management in obesity with or without type 2 diabetes
  • Glycemic control in type 2 diabetes as add-on to metformin
  • Cardiovascular risk reduction through weight loss and metabolic improvements

Choose Tirzepatide if...

  • Maximum weight loss results
  • Long-term obesity management
  • Type 2 diabetes control
  • Metabolic health improvement